This experiment proposal addresses the critical gap in understanding how alpha-synuclein (α-syn) pathology spreads through the nervous system in Parkinson's Disease. While the prion-like propagation hypothesis is widely accepted, the molecular mechanisms governing neuronal-to-neuronal transmission, templated aggregation, and selective vulnerability remain poorly characterized.
A multiscale computational model integrating protein structure, neuronal connectivity, and electrophysiology can predict:
Aim 1: Build a mechanistic model of α-synuclein misfolding, aggregation, and cell-to-cell transfer using existing cryo-EM structures (Scheres et al., 2020) and transfer kinetics data.
Aim 2: Integrate the propagation model with the Basal Ganglia connectome to predict spatial patterns of pathology spread.
Aim 3: Validate predictions against existing human iPSC and animal model data, then identify and rank therapeutic intervention points.
Protein-Level Modeling
Cell-Level Transmission
Network-Level Spread
| Item | Cost (USD) |
|---|---|
| Compute cluster time (20,000 core-hours) | $15,000 |
| PhD-level computational biologist (50% effort, 12 months) | $45,000 |
| Postdoctoral researcher (25% effort, 12 months) | $25,000 |
| AlphaFold2 cloud computing (estimated 500 jobs) | $5,000 |
| Software licenses (MATLAB, Mathematica) | $8,000 |
| Data access (Allen Institute datasets) | $2,000 |
| Publication and dissemination | $5,000 |
| Total | $105,000 |
| Investigator | Institution | Expertise | Geographic Region |
|---|---|---|---|
| Dr. Virginia Lee | University of Pennsylvania | α-syn biology, iPSC models | USA (East) |
| Prof. Michel Goedert | MRC LMB Cambridge | Tau and α-syn propagation | UK |
| Dr. Markus Beller | University of Frankfurt | Computational biophysics | Germany |
| Prof. Eriko Kagan | Harvard Medical School | Protein aggregation mechanisms | USA (East) |
| Dr. Stefano Plotkin | Stanford University | Systems biology modeling | USA (West) |
| Prof. Masuo Ohyama | Kyoto University | PD pathophysiology, primate models | Japan |
Note: Prioritize collaboration with non-US/EU investigators for geographic diversity
| Month | Milestone |
|---|---|
| 1-2 | Literature review, model architecture design |
| 3-4 | Protein and cell-level model construction |
| 5-6 | Network integration, initial simulations |
| 7-8 | Parameter sensitivity analysis, prediction generation |
| 9-10 | Validation against experimental data |
| 11-12 | Model refinement, manuscript preparation |
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Value (SV) | 9 | Addresses fundamental question of pathology spread; could transform understanding of PD progression |
| Feasibility (F) | 9 | All required data exists in literature; computational methods well-established |
| Novelty (N) | 9 | First integrated multiscale model of α-syn propagation; no existing comprehensive models |
| Disease Impact (DI) | 10 | Identifies novel therapeutic targets; predicts optimal intervention windows |
| Reach (R) | 8 | Findings applicable to MSA, DLB, and other synucleinopathies |
| Cost Efficiency (CE) | 10 | $105K for mechanistic insight that would require millions in experimental work |
| Time Efficiency (TE) | 8 | 12 months to validated predictions; experimental validation would take 3-5 years |
| Evidence Base (EB) | 8 | Extensive literature on α-syn structure, transfer kinetics, and connectomics |
| Addresses Uncertainty (AU) | 9 | Resolves key unknowns about propagation mechanisms and selective vulnerability |
| Translation Potential (TP) | 10 | Directly identifies drug targets; predicts patient subgroups for targeted therapy |
Total: 131/140 (SV:9×2 + F:9×1.5 + N:9×1.5 + DI:10×2 + R:8×1 + CE:10×1 + TE:8×1 + EB:8×1 + AU:9×1.5 + TP:10×2)